OC
MDLN

Oppenheimer & Co’s Medline Inc MDLN Stock Holding History

Oppenheimer & Co’s Portfolio MDLN Stock Details MDLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$211K Buy
+5,348
New +$216K ﹤0.01% 1643

Other funds holding MDLN

CG
Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return
HFCIX
H&F Corporate Investors X San Francisco, California $2.8B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
LPC
Lone Pine Capital Greenwich, Connecticut $16.4B AUM 99.7% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Oppenheimer & Co's MDLN Position: Q2 2026 in Review

Oppenheimer & Co opened a new position in Medline Inc (MDLN) in Q2 2026: 5,348 shares worth $211K. The stake represents ﹤0.01% of the portfolio and ranks #1643 among its holdings.

405 funds tracked by Wall St. Rank hold MDLN as of Q2 2026.

  • Oppenheimer & Co held 5,348 shares of Medline Inc worth $211K as of Q2 2026.
  • Medline Inc was a new Oppenheimer & Co position in Q2 2026.
  • Medline Inc made up ﹤0.01% of Oppenheimer & Co's portfolio in Q2 2026, its #1643 holding.
  • 405 funds tracked by Wall St. Rank held Medline Inc as of Q2 2026.

Based on Oppenheimer & Co's 13F filing for Q2 2026, filed 3 Aug 2026.